phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomyphacoemulsification with intraocular lens implantation combined with trabeculectomy
phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy: The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.
phacoemulsification with intraocular lens implantation combined with trabeculectomy: The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with trabeculectomy.
Study summary
A multicenter, parallel, open, non-inferior randomized controlled trial was conducted to compare the effectiveness and safety of phacotrabeculectomy and phacogoniotomy in the treatment of advanced primary angle closure glaucoma, so as to provide a better surgical alternative.
Eligibility
Sex
ALL
Min age
40 Years
Max age
80 Years
Healthy volunteers
No
* Inclusion criteria
1. Aged 40-80 years;
2. Diagnosed with advanced PACG: meet with (1) (2) (3) or (1) (2) (4)
1. At least 180-degree PAS under gonioscopy and it should cover the nasal and inferior quadrants for surgical purposes;
2. IOP \>21 mmHg with or without anti-glaucoma medication;
3. Obvious glaucomatous optic neuropathy (cup-to-disc \[C/D\] ratio≥0.7, or C/D asymmetry \> 0.2, or the rim width at the superior and inferior temporal \< 0.1 vertical diameters of optic disc);
4. With glaucomatous visual field defects, such as nasal step, arcuate scotoma, and paracentral scotoma on a reliable Humphrey analyzer using SITA-Standard 24-2 or 30-2 algorithm; mean deviation ≤ -12dB;
3. Clinically obvious cataract and uncorrected visual acuity (UCVA) \<0.63 (Early Treatment Diabetic Retinopathy Study, \[ETDRS\] chart), or need lens extraction assessed by a clinician;
4. Voluntarily participate in study and provide signed informed consent.
* Exclusion criteria a. History of ocular surgery (other than laser iridotomy or laser iriplasty) or trauma; b. With other types of glaucoma; (i.e. open angle glaucoma, secondary angle-closure glaucoma, steroidal glaucoma, angle regression glaucoma, neovascular glaucoma, nanophthalmos, pseudoexfoliation syndrome) c. The International Standardized Ratio \> 3.0 for patients receiving warfarin or anticoagulant therapy before surgery; d. With retinal disease that affects the collection of ocular parameters; f. Monophthalmia (best-corrected visual acuity \[BCVA\] \<0.01 in the non-study eye); g. With other serious systemic diseases; h. Pregnant or lactating women \* If both eyes are eligible for the study, the eye with the worse UCVA will be recruited.
Primary outcome measure(s)
Mean change of intraocular pressure — Postoperative 12, 24, 36 months. Change from baseline IOP after surgery using Goldmann or non-contact tonometer.
Trial sites (2)
Facility
City
Region
Status
Zhongshan Ophthalmic Center
Guangzhou
Guangdong
Zhongshan Ophthalmic Center
Guangdong
China
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.